7th Annual Psychopharmacology Update

7th Annual Psychopharmacology Update (Two-day Program – Fri.-Sat., Dec. 10-11, 2021)

Webinar -- 10:00 AM ET


Tentative Agenda (subject to change)
All times listed in ET

Day 1 - Friday, December 10, 2021

9:45 – 10:00 AM: Opening Remarks by Chair, Roger McIntyre, MD (University of Toronto)

10:00 - 11:00 AM: “Pharmacotherapy of Major Depression” – Manpreet Singh, MD (Stanford University)

-5 min break-

11:05 - 12:05 PM: Non-CME Educational Talk

-5 min break-

12:10 – 1:10 PM: “Pharmacotherapy of Schizophrenia” – John Kane, MD (Northwell Health)

-30-min meal break-

1:40 – 2:40 PM: “Pharmacotherapy of Anxiety Disorders” – Sanjay Mathew, MD (Baylor College of Medicine)

-5 min break-

2:45– 3:45 PM: Non-CME Educational Talk

-15 min break-

4:00 – 5:00 PM: "Managing Side Effects of Psychiatric Medications” Joseph Goldberg, MD (Mt Sinai)

-5 min break-

5:05 – 6:05 PM: “Pharmacotherapy of Antipsychotic Induced Movement Disorders” – Jonathan Meyer, MD (University of California, San Diego)

6:05 – 6:10 PM: Closing Remarks by Chair, Roger McIntyre, MD


Day 2 - Saturday, December 11, 2021

9:55 – 10:00 AM: Opening Remarks by Chair, Roger McIntyre, MD (University of Toronto)

10:00 – 11:00 AM: “Pharmacotherapy of Bipolar Depressive Spectrum Disorders” – Roger McIntyre, MD (University of Toronto)

-5 min break-

11:05 – 12:05 PM: Non-CME Educational Talk

-5 min break-

12:10 – 1:10 PM: “Pharmacotherapy of ADHD Across the Life Cycle” - Anthony Rostain, MD (University of Pennsylvania)

-30-min meal break-

1:40 – 2:40 PM: “Pharmacotherapies for Psychiatric Disorders: What Does the Future Hold” - Greg Mattingly, MD (Washington University)

-5 min break-

2:45 – 3:45 PM: Non-CME Educational Talk

-5 min break-

3:50 – 4:50 PM: “Pharmacotherapy of Premenstrual, Perimenopausal and Postpartum Depression” - Anita Clayton, MD (University of Virginia)

-5 min break-

4:55 – 5:00 PM: Closing Remarks by Chair, Roger McIntyre, MD


Anita Clayton, MD

David C. Wilson Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
University of Virginia School of Medicine
Charlottesville, Virginia

Joseph Goldberg, MD

Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

John M. Kane, MD

Professor and Chairman
Department of Psychiatry
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Glen Oaks, New York

Sanjay J. Mathew, MD

Professor and Vice Chair for Research
Psychiatry and Behavioral Sciences
Baylor College of Medicine
Houston, Texas

Greg Mattingly, MD

Associate Clinical Professor
Psychiatry, Psychopharmacology
Washington University School of Medicine
St Louis, Missouri
St Charles Psychiatry Associates
St Charles, Missouri

Roger S. McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Jonathan Meyer, MD

Clinical Professor
University of California, San Diego
La Jolla, California
Psychopharmacology Consultant
California Department of State Hospitals
Sacramento, California

Anthony L. Rostain, MD, MA

Professor of Psychiatry and Pediatrics
Perelman School of Medicine

Manpreet K. Singh, MD, MS

Associate Professor of Psychiatry and Behavioral Sciences
Stanford University
Stanford, California

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of psychiatric illness.

Target Audience 
This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, pharmacists, social workers, and psychologists engaged in the care of patients with psychiatric illness.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement evidence-based pharmacotherapy for schizophrenia, mood, and anxiety disorders
  • Discuss the latest advances in the management of premenstrual, perimenopausal, and postpartum depression
  • Summarize and review approaches to manage side effects of psychotropics
  • Evaluate the role of innovative treatments in treatment-resistant depression
  • Assess the management of TD in psychiatric patients
  • Discuss unmet needs in pharmacotherapy of ADHD across the lifecycle
  • Summarize the use of evidence-based treatments for anxiety disorders
  • Formulate treatment regimens considering the emergence of new antidepressant therapies
  • Individualize treatment choices based on efficacy, safety, long-term data considerations and unique patient characteristics



Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for up to a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity will be up to 9.0 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for up to 9.0 contact hours (0.9 CEUs) of the Accreditation Council for Pharmacy Education. UAN: UAN will be specific to each topic

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for up to 9.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Psychologist Continuing Education

Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity will offer up to 9.0 continuing education credits for psychologists

Social Work Continuing Education

As a Jointly Accredited Organization, Clinical Care Options, LLC (CCO) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. CCO maintains responsibility for this course. Social workers completing this course will receive up to 9.0 continuing education credits.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.